Pharmacologic inhibition of KAT6A using WM-1119 markedly enhanced the antitumor activity of cisplatin when applied to orthotopic ovarian cancer xenograft models (Figure 7). The gene discussed is KAT6A; the disease is ovarian carcinoma.